F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Conditions: Non-Hodgkin ' s Lymphoma Interventions: Drug: After preconditioning with chemotherapy, F01 will be evaluated. Sponsors: Shanghai Simnova Biotechnology Co.,Ltd.; Wuhan Union Hospital, China Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
Preventive Effect of I-Fiber Pearl on Body Weight and Body Fat in Obese Adults
Conditions: Overweight and Obesity Interventions: Dietary Supplement: I-Fiber Pearl; Dietary Supplement: placebo Sponsors: Chung Shan Medical University; ITSWAY BIOTECH INC. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Evaluation of gastrointestinal comfort following regular consumption of short-chain fructo-oligosaccharides (10-20 g per day) by children aged 6-12 years
Conditions: Gastrointestinal Tract Interventions: Dietary Supplement: short-chain fructo-oligosaccharides (dose 1); Dietary Supplement: short-chain fructo-oligosaccharides (dose 2); Other: Baseline Sponsors: Tereos; CEN Biotech Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants
Conditions: Rotavirus Infection of Children Interventions: Biological: ROTAVAC 5D; Other: Placebo Sponsors: Bharat Biotech International Limited Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
Off-the-shelf CD123 CAR-NK for R/R AML
Conditions: Acute Myeloid Leukemia, in Relapse; Acute Myeloid Leukemia Refractory Interventions: Drug: JD123 injection Sponsors: Peking University People ' s Hospital; Beijing JD Biotech Co. LTD. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
Open-Label Study of Vaginal AZU-101 in Postmenopausal Women
Conditions: Postmenopausal Symptoms Interventions: Drug: Lasofoxifene Tartrate (AZU-101); Drug: Lasofoxifene Tartrate (AZU-101); Drug: Lasofoxifene Tartrate (AZU-101); Drug: Lasofoxifene Tartrate (AZU-101); Drug: Lasofoxifene Tartrate (AZU-101) Sponsors: Azure Biotech Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil ®9 in Young Women
Conditions: Cervical Cancer; Condylomata Acuminata Interventions: Biological: Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli); Biological: Gardasil ®9 Sponsors: Xiamen Ophthalmology Center Affiliated to Xiamen University; Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)
Conditions: Advanced Gastrointestinal Tumors Interventions: Biological: LCAR-G08 cells Sponsors: Peking University; Nanjing Legend Biotech Co. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 9, 2024 Category: Research Source Type: clinical trials
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera
Conditions: Cholera Interventions: Drug: VR-AD-1005; Drug: Placebo Sponsors: Hunazine Biotech S.L. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)
Conditions: Adult; Gynecological Tumors Interventions: Biological: Autologous tumor infiltrating lymphocyte injection （GT201） Sponsors: Grit Biotechnology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma
Conditions: HNSCC; Adults Interventions: Biological: GT201 in combination with PD-1 inhibitors Sponsors: Grit Biotechnology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials
Phase I/IIa Study of SNK01 in Participants With Moderate Alzheimer's Disease
Conditions: Moderate Alzheimer Disease Interventions: Biological: SNK01; Other: Placebo Sponsors: NKGen Biotech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Clinical Study of GT201 Combined With PD-1 Inhibitor in the Treatment of Advanced Head and Neck Squamous Cell Carcinoma
Conditions: HNSCC; Adults Interventions: Biological: GT201 in combination with PD-1 inhibitors Sponsors: Grit Biotechnology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
Conditions: Moderate Alzheimer Disease Interventions: Biological: SNK01; Other: Placebo Sponsors: NKGen Biotech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis
PALO ALTO, Calif., Jan. 3, 2024 Genascence Corporation ( " Genascence " ), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the initiation of its... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 3, 2024 Category: Pharmaceuticals Source Type: clinical trials
